Table II.
Clinical trials targeting GDF15 in patients with cancer and CC.
| Clinical trial identifier | Start year | Compound/dr ug | Participants, n | Disease | Phase | Status | Results | Locations | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|
| NCT05865535 | 2023 | AV-380 | 30 (estimated) | Colorectal and pancreatic CC | I | Recruiting | NA | USA | NA |
| NCT05546476 | 2022 | Ponsegromab | 168 (estimated) | Non-small cell, pancreatic and colorectal CC | II | Recruiting | NA | Spain, Taiwan, USA, Australia, Bulgaria, Canada, China, Czechia, Hungary, Japan, Poland, Slovakia | NA |
| NCT04803305 | 2021 | Ponsegromab | 18 (actual) | Non-small cell lung, pancreatic, colorectal, prostate, breast and ovarian CC | I | Completed | NA | Canada, USA | NA |
| NCT04299048 | 2020 | Ponsegromab | 11 (actual) | Non-small cell lung, pancreatic and colorectal CC | Ib | Completed | Compared with controls, patients treated with ponsegromab had lower circulating GDF-15 levels and increased body weight, physical activity and appetite | USA | (92) |
| NCT04725474 | 2020 | CTL-002 | 155 (estimated) | Adult solid tumor | I/II | Recruiting | NA | Germany, Spain, Switzerland | NA |
| NCT05397171 | 2022 | AZD8853 | 16 (actual) | Bladder, colorectal and non-small cell lung cancers | II | Terminated | NA | Canada, USA | NA |
Data in the table are from ClinicalTrials.gov. CC, cancer cachexia; GDF15, growth differentiation factor 15; NCT, National Clinical Trial; NA, not available.